Drug intelligence / Profile preview

SPM-929

Development stage: Unknown
Lead developer: UCB
Administration: Oral

Overview

SPM-929 is an investigational drug candidate developed by UCB, currently in Phase 3 clinical trials for the treatment of Painful Diabetic Neuropathy. Further details regarding its specific mechanism of action are not publicly available.

Beyond the preview

Go deeper on SPM-929.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPM-929.

Explore the full profile